

To participate in 'Fire in the Lake: War Raging Over Endometriosis' lecture activities please link to:

attend.sl/se47



PEINWEEK.

War Raging Over Endometriosis

Georgine Lamvu, MD, MPH

Professor of Obstetrics and Gynecology and Pelvic Pain Specialist University of Central Florida

Disclosures

- Consultant: Abbvie
- Myovant
- SoLá Pelvic Therapy
- Medical Learning Institute (MLI-Peer Review)



Audience Participation

Please silence your phones



To participate in audience poll, ask questions and view slides







What state or country are you from?

Vote at:

What state or country are you from?



Time left: 10



What is your specialty?

Vote at: attend.sl/se47

What is your specialty?





Learning Objectives

Review pathophysiology of endometriosis Compare treatment interventions

2

Discuss treatment selection controversies

3



Virtual Wome







26 yo, dysmenorrhea, fibroids, depression 29 yo, CPP, dyspareunia, urgency, frequency, constipation, anxiety, depression

32 yo, infertility, dyspareunia, anxiety, marital discord

ENDOMETRIOSIS



Do you agree with virtual woman #1 not having a surgical diagnosis of endometriosis?



Time left: 5

Vote at: attend.sl/se47

Votes: 0

Do you agree with virtual woman #1 not having a surgical diagnosis of endometriosis?







Virtual Women



26 yo, dysmenorrhea, fibroids, depression

Treatments: Birth control pills 29 yo, CPP, vulvodynia, urgency, frequency, constipation, anxiety, depression

Treatments:

Birth control pills Hysterectomy

Antidepressants

 ³² yo, infertility, dyspareunia, anxiety, marital discord
Treatments:
Laparoscopy x 4
Analgesics
Antidepressants

SYMPTOMS CONTINUE





Do you agree with virtual woman #4 having 4 laparoscopies for endometriosis?



Time left: 5

Votes: 0

Do you agree with virtual woman #4 having 4 laparoscopies for endometriosis?







Originally defined as endometrial cells implanting outside the uterus

NEW- re-classified as endometrial-like cells (cells similar to endometrial cells) implant outside the uterus, it differs from endometrium in that it can cause inflammation, fibrosis **NEW-** emphasis on differentiating superficial from deep infiltrating endometriosis found in the rectovaginal septum, bladder and bowel

Painweek.

Endometriosis



https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline.

Disclaimer

Because this is Painweek, we will focus on Endometriosis associated pain



Mechanisms of Pain in Endometriosis



 Chronic inflammation characterized by systemic and local cytokines and growth factors resulting in pain

 NEW: Long-term exposure to these pro-inflammatory substances can lead to peripheral and central sensitization, hyperalgesia, and chronic pain



Pathophysiology and Epidemiology

- Estrogen stimulates lesion growth, inflammation, and pain
- •6%-10% of women of reproductive age in the United States have endometriosis
- **NEW:** On average, women experience pain for 6-10 years
- •55% of women see three or more doctors before the diagnosis is made

Burney RO, Giudice LC. Fertil Steril. 2012. Fuldeore MJ, Soliman A. *Gynecol Obstet Invest*. 2017. Mowers EL et al. *Obstet Gynecol.* 2016. Green R et al. *Fertil Steril*. 2009. Zondervan KT et al. *N Engl J Med*. 2020.



Symptoms of Endometriosis

Primary symptoms

-Pain and infertility

Other common symptoms

- -Painful menstrual cramps
- -Pain during/after sex
- –Painful bowel movements or urination during menstrual periods
- -Heavy menstrual periods

Meek

.

-Premenstrual spotting or bleeding between periods

Symptoms are more common in younger women (aged 18-29 years)

- 73% dysmenorrhea
- 57% noncyclical pelvic pain
- 43% dyspareunia

In women of reproductive age, the triad of dysmenorrhea, noncyclic pelvic pain, and dyspareunia (± infertility) should trigger an evaluation for endometriosis to prevent delay in diagnosis

Fuldeore MJ, Soliman A. *Gynecol Obstet Invest*. 2017. Mowers EL et al. *Obstet Gynecol*. 2016. https://www.nichd.nih.gov/health/topics/endometri/conditioninfo/symptoms.

Diagnosis

History

Pelvic exam

- Pelvic ultrasound adequate for large lesions, endometriomas, but not smaller implants or adhesions
 - MRI: deeply may be helpful for invasive endometriosis (e.g., bowel, bladder)
 - NO: Serum markers (CA-125, cytokines, MCP1, adhesion molecules) are nonspecific





Therapy Options for Endometriosis Symptoms



Kuznetsof L et al. *BMJ*. 2017, ACOG Practice Bulletin No. 114. *Obstet Gynecol*. 2010, <u>https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline</u>, Hirsch M et al. *BJOG*. 2018, Fuldeore MJ, Soliman A. *Gynecol Obstet Invest*. 2017, Zondervan KT et al. *Nat Rev Dis Primers*. 2018, Zondervan KT et al. *N Engl J Med*. 2020.

Traditional Treatment Regimens



FDA-Approved Pharmacotherapy for Endometriosis

Treatment	Туре	Year Approved
Norethindrone	Synthetic progestin	2005
Medroxyprogesterone acetate	Progestin	2005
Leuprolide acetate	GnRH agonist	1999
Nafarelin acetate	GnRH agonist	1990
Goserelin acetate	GnRH agonist	1989
Danazol	Synthetic androgen	1971
Elagolix	GnRH antagonist	2018



LNG-IUD for Endometriosis is Comparable to GnRH Agonist

Human Reproduction Vol.20, No.7 pp. 1993–1998, 2005 Advance Access publication March 24, 2005 doi:10.1093/humrep/deh869

Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis

Carlos A.Petta^{1,4}, Rui A.Ferriani², Mauricio S.Abrao³, Daniela Hassan¹, Julio C.Rosa e Silva², Sergio Podgaec³ and Luis Bahamondes¹



Figure 2. Changes in the visual analogue score pain scores between the two treatment groups. Values are mean \pm SEM. *P*-value: not Figure 3. Changes in the bleeding scores between the two treatment groups. Values are mean \pm SEM. *P*-value: not Figure 3. Changes in the bleeding scores between the two treatment groups. Values are mean \pm SEM.



GnRH Antagonist: Elagolix

Reduction of Dysmenorrhea and Non-menstrual Pelvic Pain

Double-blind, RCT

Painweek

- Primary endpoint: clinically meaningful reduction in pain
- 872 patients randomized and followed over 6 months, trial extended for additional 12 months
- FDA approved for 24 months of use
- AEs: hot flushes and mild bone density loss



Taylor HS et al. *N Engl J Med*. 2017;377:28-40. 2. https://www.accessdata.fda.gov/scripts/cder/daf/.

Surgery for Endometriosis

- Ablation
 - -Superficial
- Excision
 - -Superficial
 - –Deep
- Hysterectomy
 - -± Salpingoophrectomy



richie graham, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons





What proportion of women report improvement in pain after laparoscopic treatment (excision or ablation) of endometriosis?

What proportion of women report improvement in pain after laparoscopic treatment (excision or ablation) of endometriosis?







Meta-analysis of Laparoscopic Treatment Cochrane 2006



Painweek

In these studies, 60-80% of patients who had laparoscopic treatment reported improvement in pain

Jacobson TZ, et al. The Cochrane database systematic reviews, 2006.

Meta-analysis of Laparoscopic Treatment, Odd of Improvement

Duffy JM, et al. Cochrane, 2014.

Population: Women with mild to moderate endometriosis Settings: Any setting Intervention: Laparoscopic ablation or excision Comparison: Diagnostic laparoscopy					
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% Cl)	No of Participants (studies)	
	Assumed risk	Corresponding risk			
	Diagnostic Iaparoscopy	Laparoscopic ablation or excision			
Overall pain better or improved at 6 month follow-up	321 per 1000	756 per 1000 (610 to 861)	OR 6.58 (3.31 to 13.10	171 (3 Studio s)	
Overall pain better or improved at 12 month follow-up	214 per 1000	732 per 1000 (467 to 895)	OR 10.00 (3.21 to 31.17)	69 (1 Study)	
Live birth or ongoing pregnancy	179 per 1000	297 per 1000 (207 to 408)	OR 1.94 (1.20 to 3.16)	382 (2 Studies)	
Clinical pregnancy	186 per 1000	302 per 1000 (223 to 396)	OR 1.89 (1.25 to 2.86)	528 (3 Studies)	
Miscarriage (per preg- nancy)	190 per 1000	181 per 1000 (76 to 374)	OR 0.94 (0.35 to 2.54)	112 (2 Studies)	



Laparoscopic Ablation vs. Diagnostic Laparoscopy + GnRH Agonist

Figure 6. Forest plot of comparison: 2 Laparoscopic versus diagnostic laparoscopy and medical therapy, outcome: 2.1 Ablation versus diagnostic laparoscopy and GnRHa (and add-back therapy).



Test for subgroup differences: Not applicable

OR for 'pain free' at 12 months 5.63 (95%CI: 1.18-26.85)

Duffy JM, et al. Cochrane, 2014.





At the time of laparoscopy, is it better to ablate or excise the endometriosis?

At the time of laparoscopy, is it better to ablate or excise the endometriosis?





Review Article

Laparoscopic Excision Versus Ablation for Endometriosis-associated Pain: An Updated Systematic Review and Meta-analysis

Jyotsna Pundir, MD*, Kireki Omanwa, MRCOG, Elias Kovoor, MD, Vishal Pundir, MS, Gillian Lancaster, PhD, and Peter Barton-Smith, MD

Table 3						
Quality of studies included in the systematic review of laparoscopic excision versus ablation for endometriosis-associated pain						
Author	Method of randomization	Allocation concealment	Blinding	Intention-to-treat analysis	Follow-up rate (%)	Design
Barton – Smith 2010	Random sequence generation in blocks of 10	Yes	Double	Yes	77	Randomized double blind
Healey et. al., 2010	Computer-generated random numbers	Yes	Double	Yes	58	Randomized double blind
Wright et. al., 2005	Random sequence generation in blocks of 10	ND	ND	ND	100	Randomized double blind

'The limited available evidence shows that at 12 months post surgery, symptoms of dysmenorrhea, dyschezia, and chronic pelvic pain secondary to endometriosis showed significantly greater improvement with laparoscopic excision compared with ablation.'



Pundir et al, Journal of Minimally Invasive Gynecology 2017

Endometriomas: Excise or Drain & Ablate?

Outcome		OR (95% CI)	
Recurrence of Symptoms:			
Dysmenorrhea		0.15 (0.06, 0.38)	
Non-menstrual pain		0.10 (0.02, 0.56)	
Dyspareunia		0.08 (0.01, 0.51)	
Recurrence of endometrioma		0.41 (0.18, 0.93)	
odds ratio	0.1 1	10 100	
Favor	Favors excision		

Hart RJ, Hickey M, Maouris P, Buckett W. Cochrane Database Syst Rev. 2008.

Painweek.
Hysterectomy for Endometriosis-Associated CPP

Likelihood of another surgery within 7 years of 1st surgery



Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Obstet Gynecol. 2008

Painweek.



If we know so much about Endometriosis...

Why is there so much discussion / confusion?



MD - Endometriosis and Pelvic Pain

I have patients/doctors asking about ablation versus excision. In my opinion, excision is the key. Not only for removing the disease (which can be accomplished in some patients with ablation), but to obtain estrogen and progesterone receptors on all of the specimens removed. In my 14 years of doing this, 75% of the receptors are positive for both estrogen and

Birth control pills have ruined my life. I wish that I never would have taken them to control endo and cysts in the first place. 17 years of poison, and almost loss of life and now I get it! NO MORE!!

- Endometriosis and Pelvic Pain is with

Heading home from my Second Look surgery. Dr said that it looked PERFECT when he went back inside. He told me only thing was a big adhesion that grew back connecting my left ovary to my side wall which hurt a lot. But it was detached and fixed. The good news? 70% that it won't come back. A Follow up in two weeks with pathology. VIII be trying for now.-

















Difficulty in making the diagnosis





There are no biological markers proven to reliably confirm presence of endometriosis. (Liu, Nisenblat et al. 2015, Gupta, Hull et al. 2016, Nisenblat, Bossuyt et al. 2016, Nisenblat, Prentice et al. 2016, Nisenblat, Sharkey et al. 2019, Anastasiu, Moga et al. 2020)



 Laparoscopy with pathologic confirmation is the only way definitively diagnose endometriosis.



 Even after laparoscopic confirmation, stage of endometriosis does not correlate to symptoms severity. (Schliep, Mumford et al. 2015, Vercellini, Trespidi et al. 1996, Fedele, Parazzini et al. 1990, Conroy, Mooney et al. 2021)



Treatment Recommendations For Endometriosis- North American Guidelines

ASRM (2014)

Establishing the correct diagnosis with laparoscopy before initiating therapy with medication that is associated with significant short-term and long-term side effects is the preferred approach, although further studies are warranted. (The Practice Committee ASRM, Fert Steril, 2014)

ACOG (2010)

The definitive diagnosis of endometriosis can only be made by histology of the lesions removed at surgery. After appropriate pretreatment evaluation and failure of COCs and NSAIDS, empiric therapy with a 3-month course of GnRH agonists is appropriate. (ACOG Practice Bulleting, Obstet Gynecol, 2010)

SOGC (2013)

The gold standard is direct visualization at laparoscopy and histologic study. Diagnostic laparoscopy is not required before treatment in all patients presenting with pelvic pain. (Leyland N. et.al. J Obstet Gynaecol Can, 2010) PainWeek.



Patients may present with pain (dysmenorrhea, dyspareunia, CPP) and have no obvious endometriosis on laparoscopic examination. (Walter, Hentz et al. 2001, Ling 1999)



Other conditions (IC/Bladder Pain Syndrome (BPS), IBS) may present with similar symptoms, 70-80% of women with endometriosis have BPS.(Chung, et al. 2002, Chung, et al. 2005, Tirlapur, Kuhrt et al. 2013)



Treatment Effectiveness

A second look at the data...



Response to medical therapy and symptom recurrence after treatment cessation. Becker, Gattrell et al. 2017: Systematic Review

Proportions of patients with (A) no reduction in pain symptoms, (B) pain symptoms remaining at end of treatment, and

(**C**) recurrence of pain symptoms after treatment cessation.

Painweek



Results are presented as median (range). ND = no data; CHC = combined hormonal contraceptive

Meta-analysis of Laparoscopic Treatment Cochrane 2006



Limitations: Few studies, small sample size, Wide confidence intervals

Not all patients respond, 18%-38% do not respond Placebo rate is high, 22-43% in diagnostic laparoscopy alone report improvement



Jacobson TZ, et al. 2006.

Laparoscopic surgery for endometriosis: Systematic Review Bafort C, et al. Cochrane 2020

14 RCTS, 1563 women with endometriosis

Main conclusion

 Laparoscopic treatment vs. diagnostic laparoscopy, very low-quality evidence insufficient evidence to determine whether laparoscopy helps pain

-Not enough evidence to show that excision favors ablation



Review Article

Laparoscopic Excision Versus Ablation for Endometriosis-associated Pain: An Updated Systematic Review and Meta-analysis

Jyotsna Pundir, MD*, Kireki Omanwa, MRCOG, Elias Kovoor, MD, Vishal Pundir, MS, Gillian Lancaster, PhD, and Peter Barton-Smith, MD

Dysmenorrhea no benefit



Dyschezia favors excision



Dyspareunia no benefit



Pundir et al, Journal of Minimally Invasive Gynecology 2017

CPP favors excision, one study only



Quality of life favors excision, one study only



Same or worse at 12 months:

- Excision 14.6%
- Ablation 27.2% P=0.13

Significant Study Limitations

- Small sample sizes
- Large loss to follow-up
- Conflict of interest not stated: members of the authorship team were 1) related and 2) authors on one of the papers evaluated as favoring excision
- Overall, this was a poor meta-analysis and conclusions cannot be made in favor of either technique



Recurrence in Deep Infiltrating Endometriosis: A Systematic Review

- Inconsistencies and heterogeneity in data reporting, case definition, and outcome definition; could not complete a meta-analysis
- Recurrence rate 2%-43.5%
- Risk factors for recurrence: young age, weight, and incomplete resection



Ianieri, M, Mautone D, Ceccaroni M, J Minim Invasive Gynecol, 2018

Pain Recurrence After 1st Conservative Surgery



Figure 1 Pain recurrence or re-operation rates reported after first-line conservative surgery for symptomatic endometriosis. Literature data, 1991–2008, observational and retrospective studies. Diamonds represent percentage point estimates and horizontal lines 95% confidence intervals. *Cumulative dysmenorrhoea recurrence rate after surgery at laparotomy; †Cumulative re-operation rate; ‡Only subjects with moderate to severe dysmenorrhoea are considered; §Dyspareunia recurrence rate at intention-to-treat analysis.

Painweek

Vercellini et al. Hum Repro Update 2009.

Time to Recurrent Pain after 1st Surgery



Figure 2 Cumulative 36 month probability of recurrence of moderate or severe dysmenorrhoea by disease stage in 425 symptomatic women who underwent conservative surgery for endometriosis (black line, stage I; red line, stage II; blue line, stage III; green line, stage IV). From Vercellini *et al.* (2006a), reproduced with permission of the publisher.

Vercellini et al. Hum Repro Update 2009.

Painweek.

Hysterectomy Likelihood of Success (No Re-operation) **Depends on Age and Ovarian Preservation**

BSO: 8.3%

Operative Laparoscopy: 55

NM/eek



Preserve ovaries in younger women (when feasible), because removal of ovaries does not reduce reoperation

Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Obstet Gynecol. 2008 Jun;111(6):1285-92

Nearly 50% of women with endometriosis have recurrent symptoms within 5 years, regardless of the treatment approach. (Zondervan, Becker et al. 2020, Becker, Gattrell et al. 2017)



So how do we win the war of endometriosis?

- Pay attention to the evidence
- Don't pooh pooh medical therapy
- Don't over-promise surgical therapy





How can we improve outcomes?



Hormonal Suppression

 Progestins are preferred to COCs, and continuous suppression of menstruation is preferred over cyclic. (Seracchioli R et al. *Fertil Steril.* 2010; Muzii L et al. *Am J Obstet Gynecol.* 2016)

	Continuous Cyclic				Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Momoeda 2017	11.9	9.4	105	15.3	11.8	107	35.5%	-3.40 [-6.27, -0.53]	
Strowitzki 2012	10.6	6.7	112	14.9	8.9	102	64.5%	-4.30 [-6.43, -2.17]	•
Total (95% CI)			217			209	100.0%	-3.98 [-5.69, -2.27]	•
Heterogeneity: Chi ² = 0.24, df = 1 (P = 0.62); l ² = 0%									-100 -50 0 50 100
Test for overall effect: $Z = 4.57$ (P < 0.00001)								F	Favours [experimental] Favours [control]

Pai

Damm, T., Lamvu, G., Carrillo J., Ouyang, C., Feranec, J., Contraception X, 2019

Post Cystectomy Medical Therapy Reduces Rate and Size of Recurrent Endometrioma



Recurrence free survival is higher in OCP users vs. non-users.

In those with recurrent endometriomas, users of OCPs had smaller cysts.



Post-operative OCPs Following Excision of Ovarian Endometrioma: Continuous or Cyclic?

Outcome		OR (95% CI)
Recurrence of Pain Symptoms:		
Dysmenorrhea (n=287) ——		0.24 (0.06, 0.91)
Non-menstrual pain (n=209)		- 0.61 (0.36, 1.03)
Dyspareunia (n=180)		— 0.77 (0.52, 1.12)
Recurrence of endometrioma (n=154)		- 0.54 (0.28, 1.05)
odds ratio	0.2 0.5	2 5

Favors continuous

Painweek.

Muzii L, et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016 Feb;214(2):203-11.

Favors cyclic

Hormonal Suppression Following Surgery

Endometriosis recurrence following post-operative hormonal suppression: a systematic review and meta-analysis.

'When hormonal suppression (CHC, progestin, LNG-IUS, GnRH agonist) is initiated within 6 weeks of endometriosis surgery, there is a significant reduction in endometriosis recurrence and pain scores at up to 1 year post-operatively. Medical suppression should be considered and discussed with patients not seeking pregnancy immediately after surgery. As various hormonal agents have been shown to be effective, the choice of treatment should be individualized according to each woman's needs'

Zakhari, A, et.al. Human Reproductive Update, 2021.



Risk of radiologic or clinical endometriosis recurrence with postoperative hormonal suppression compared to expectant management

	Treatm	ent	Contr	ol					
Study	Events	n	Events	n	Risk R	latio	RR	95	% CI
Campo (2014)	12	46	16	102	1	-	1.66	[0.86; 3	3.23]
Cucinella (2013)	9	130	14	38			0.19	[0.09; 0	0.40]
Hornstein (1997)	15	49	25	44	<u></u> ,	-1	0.54	[0.33; 0	0.88]
Huang (2018)	6	50	15	50		_	0.40	[0.17; 0	0.95]
Muzii (2000)	2	33	1	35			→ 2.12	[0.20; 22	2.31]
Seracchioli (2010)	17	148	20	69		er	0.40	[0.22; 0	0.71]
Sesti (2009)	15	118	10	60		-	0.76	[0.36;	1.59]
Takaesu (2016)	12	105	17	79		-	0.53	[0.27;	1.05]
Tanmahasamut (2012)	2	27	9	23	← *	-	0.19	[0.05; 0	0.79]
Vercellini (1999)	14	107	22	103		+	0.61	[0.33;	1.13]
Vercellini (2003)	2	20	9	20	< <u> </u>	-1	0.22	[0.05; 0	0.90]
Vercellini (2008)	9	102	26	46	<u>← </u>		0.16	[0.08; 0	0.31]
Yang (2006)	1	19	4	13	<	<u> </u>	0.17	[0.02; *	1.36]
Yang (2019)	1	65	9	65	(-	0.11	[0.01; (0.85]
Fixed effect model	117	1019	197	747	+		0.46	[0.37; 0	.56]
Random effects model								[0.26; 0	-
Prediction interval Heterogeneity: $I^2 = 68\%$, t	$^{2} = 0.4671$	n < (0.01			-		[0.09; 1	.96]
	0.107	, p · c		0.	08 0.5	1 2	5		

Figure 2. Risk of radiologic or clinical endometriosis recurrence with post-operative hormonal suppression compared to expectant management.

Zakhari, A, et.al. Human Reproductive Update, 2021.

Painweek

Risk of endometriosis recurrence by hormonal method

	Studies	Patients	I ²	Relative Risk (95% CI)	
СНС	6	854	67%	0.36 (0.15 - 0.87)	
Progestin*	1	32	NA	0.17 (0.02 – 1.36)	
LNG-IUS	2	90	0.0%	0.21 (0.07 - 0.57)	
GnRH-a	7	929	52%	0.62 (0.35 - 1.13)	0.05 0.10 0.20 0.50 1.00 1.50

Figure 3. Relative risk of endometriosis recurrence by hormonal intervention (random effects). CHC, combined hormonal contraceptive; CI, confidence interval; LNG-IUS, levonorgesterel intra-uterine system. *Single study—fixed effect model.

Zakhari, A, et.al. Human Reproductive Update, 2021.

Pai

NW COK

Change in pain scores with post-operative hormonal suppression compared to expectant management

		I reat	ment		Cont	rol	Standardised Mean		
Study	Total	Mean	SD	Total	Mean	SD	Difference	SMD	95%-
Angioni (2015)	80	-11.60	26.6949	79	-9.72	27.6276		-0.07	[-0.38; 0.3
Dobrokhotva (2017)	12	-6.00	2.5660	9	-2.00	2.5660			[-2.50; -0.5
Hornstein (1997)	49	-3.15	2.6600	44	-0.97	2.2800	- 	-0.87	[-1.30; -0.4
Huang (2018)	50	-3.90	4.3991	50	-3.80	4.9642		-0.02	[-0.41; 0.3
Sesti (2007)	77	-2.24	1.8689	110	-1.50	2.1656		-0.36	[-0.66; -0.0
Tanmahasamut (2012)	28	-81.00	26.6667	26	-50.00	57.7778		-0.69	[-1.24; -0.1
Vercellini (2003)	19	-57.00	29.0593	19	-36.00	39.4266		-0.59	[-1.24; 0.0
Fixed effect model	315			337			•	-0.37	[-0.53; -0.2
Random effects model							-	-0.49	[-0.91; -0.0
Prediction interval									[-1.62; 0.6
Heterogeneity: $I^2 = 68\%$, τ^2	= 0.16	33, p < 0	0.01						

Figure 4. Change in pain scores with post-operative hormonal suppression compared to expectant management.

Painweek

Zakhari, A, et.al. Human Reproductive Update, 2021.

Other Factors Matter: Influence of Depression on Risk of Persistent Pain

Table 4. Pain, Sexual Function, and Satisfaction With Outcome of Surgery by Preoperative Depression and Pain Status

			Preop	erative status	
Outcomes	n	Pain only	Depressed only	Depressed with pain	Not depressed without pain (referent group)
Pelvic pain as a problem* ^{†‡§}					
6 months	1,080	2.39(1.43 - 4.02)	1.78(0.96 - 3.30)	4.49 (2.63 - 7.69)	1.00
24 months	1,031	2.22 (1.17-4.23)	1.42(0.65 - 3.10)	4.91 (2.63-9.16)	1.00

"Women with pelvic pain (OR 2.22), depression (OR 1.42) and both pain + depression (OR 4.91) fared less well 24 months after hysterectomy than women who have neither."

Painweek

Hartmann KE, Ma C, Lamvu GM, et. Al. Obstet Gynecol. 2004 Oct; 104(4):701-9.

Summary: Evidence on Endometriosis-Associated Chronic Pelvic Pain

- All treatments, except hysterectomy, are considered <u>suppressive</u> rather than curative; endometriosis is a chronic disease requiring sustained treatment and suppression of menstruation¹⁻³
- Can have significant physical, sexual, psychological, and social effects requiring long-term treatment.¹⁻⁵ Biopsychosocial evaluation and treatment is needed⁶

In many cases, endometriosis is not the only contributor to pain, thus multiple causes of pain must be considered...even in patients with surgically confirmed endometriosis (especially if the pain persists after surgery). ^{1,9}

> 1. https://www.nice.org.uk/guidance/ng73/chapter/Recommendations. 2. https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Endometriosis-guideline. 3. Abou-Setta AM et al. *Cochrane Database Syst Rev.* 2013; 4. Falcone T, Flyckt R. *Obstet Gynecol.* 2018. 5. Vercellini P et al. *Hum Reprod Update.* 2009; 6.Allaire C et al. *J Endometr Pelvic Pain Disord.* 2017;7. Seracchioli R et al. *Fertil Steril.* 2010;94:856-861. 8. Muzii L et al. *Am J Obstet Gynecol.* 2016;214:203-211. 9. Falcone T, Flyckt R, 2018;

Painweek

Summary: Evidence on Endometriosis-Associated Chronic Pelvic Pain

- When using medical therapy
 - -Full suppression of menstruation with continuous regimens is recommended in women with endometriosis associated pain and / or dysmenorrhea
 - -Progestins are preferred over E/P hormonal regimens
 - -Expect that therapies will not be effective long term (~ every 2 years)
- When using surgical therapy
 - –Up to 40% of patients do not respond, recurrence rates are high; 15%-50% have recurrent pain or reoperation within 2 years
 - -Medical suppression with progestins, LNG-IUD, GnRH analogues or combination contraceptives delays recurrence of pain after conservative surgery
- Hysterectomy is beneficial for pain relief; however, ovarian preservation is recommended in women aged <40 years as oophorectomy is associated with severe menopausal symptoms and increased all-cause mortality

Painweek.

PEINWEEK.

All women with endometriosis should be counseled that:

- Stage is not predictive of symptoms or outcome and not all endometriosis is the same... endometriomas respond to therapy, but wide-spread endometriosis is more complex.
- Medical (before and after surgery) *AND* surgical excision (or ablation) will likely be needed to control severe symptoms long-term and that neither option is a 'cure' for endometriosis.

Patient Education Resources

www.pelvicpaineducation.com

Education Mak	es a Difference	e						
	ELVIC AIN DUCATIO ROGRAM					P	Pain education helps manage and improve quality o	
PEP OVERVIE	N PATIE	INTS	VETERANS	PPEP VIDEOS	FAQs and TESTS	RESOURCES	HEALTHCARE PROFESSIONALS	MORE



PROGRAM OVERVIEW

For the millions living with persistent pelvic pain, the biggest problem is access to information and pain specialists. The Pelvic Pain Education Program (PPEP) is a pain education program for persons suffering with complex **pelvic** pain conditions. The primary mission of the program is to increase knowledge and awareness about pelvic pain because this has been shown, by research, to decrease pain and improve quality of life. PPEP provides **you** with resources for pain management. Although the program foccuses on



Painweek.

24th Annual Scientific Meeting on Pelvic Pain www.pelvicpain.org

- Attend face-to-face or virtual
- Foundations course on October 21 for new HCPS
- Trigger point injections, and myofascial manipulation course on October 24

Painweek.



Thank you

 Contact Email: <u>Georgine.Lamvu@va.gov</u>

Submit additional questions and evaluation at



